7-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-8-methoxy-1,6-naphthyridine-5-carboxylic acid | 1149734-40-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-8-methoxy-1,6-naphthyridine-5-carboxylic acid
• CAS: 1149734-40-6
• 化学式: C₁₉H₁₃FN₄O₄
• 分子量: 380.335
• InChiKey: FFKVMMLGUKRBRU-UHFFFAOYSA-N

物化性质

• 沸点：
  667.4±65.0 °C(predicted)
• 密度：
  1.437±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.12
• 重原子数：
  28.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  111.23
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  7-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-8-methoxy-1,6-naphthyridine-5-carboxylic acid 在 三甲基氯硅烷 、 sodium iodide 作用下， 以 乙腈 为溶剂， 生成 7-[5-[(4-Fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-8-hydroxy-1,6-naphthyridine-5-carboxylic acid
  参考文献：
  名称：

  1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position

  摘要：

  The use of a 1,3,4-oxadiazole in combination with an 8-hydroxy-1,6-naphthyridine ring system has been shown to deliver potent enzyme and antiviral activity through inhibition of viral DNA integration. This report presents a detailed structure-activity investigation of the C5 position resulting in low nM potency for several analogs with an excellent therapeutic index. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.089
• 作为产物：
  描述：

  methyl 7-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-8-methoxy-1,6-naphthyridine-5-carboxylate 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以89%的产率得到7-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-8-methoxy-1,6-naphthyridine-5-carboxylic acid
  参考文献：
  名称：

  1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position

  摘要：

  The use of a 1,3,4-oxadiazole in combination with an 8-hydroxy-1,6-naphthyridine ring system has been shown to deliver potent enzyme and antiviral activity through inhibition of viral DNA integration. This report presents a detailed structure-activity investigation of the C5 position resulting in low nM potency for several analogs with an excellent therapeutic index. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.089